EU MDR Compliance Costs Surge as Cobalt, NMP Broaden Scope
Event summary
- Claigan Environmental is hosting two webinars on February 26, 2026, detailing EU MDR Justification Document requirements.
- The webinars focus on CMR (carcinogen, mutagen, reproductive toxin) compliance under the EU MDR, specifically addressing the recent inclusion of cobalt and NMP.
- The MDR mandates justification documents for medical devices containing CMRs in invasive, fluid, or gas paths.
- Affected products include needles, catheters, ventilators, and glucose monitoring systems, representing a significant portion of the medical device market.
- Claigan Environmental claims to have tested thousands of products for EU MDR compliance.
The big picture
The EU MDR’s tightening of CMR substance regulations represents a broader trend toward stricter environmental and health standards in the medical device sector. This shift, driven by increasing public awareness and regulatory pressure, is forcing manufacturers to re-evaluate material choices and compliance processes. The need for specialized consulting and testing services, as demonstrated by Claigan's webinar, highlights the growing complexity and cost associated with maintaining market access in Europe.
What we're watching
- Regulatory Headwinds
- The expansion of CMR substances requiring justification will likely increase compliance costs and complexity for medical device manufacturers, potentially impacting profit margins and product timelines.
- Service Demand
- Demand for specialized compliance services like those offered by Claigan Environmental is expected to remain high, as manufacturers grapple with the evolving regulatory landscape and seek expert guidance.
- Market Impact
- The increased scrutiny of CMR substances may lead to a shift in material selection within the medical device industry, potentially favoring alternative materials and impacting existing supply chains.
Related topics